Quick Answer
IGC Pharma, Inc. reported Long-Term Debt of $134.0 thousand for fiscal year 2025.
IGC Pharma, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $134.0K | -2.2% |
| 2024 | $137.0K | -2.8% |
| 2023 | $141.0K | -2.1% |
| 2022 | $144.0K | -47.8% |
| 2021 | $276.0K | — |
| 2020 | $0.00 | -100.0% |
| 2017 | $452.1K | -43.6% |
| 2016 | $801.5K | +147.4% |
| 2015 | $323.9K | — |
| 2014 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $132.0K | -2.2% | -0.8% |
| June 30, 2025 | $133.0K | -2.2% | -0.7% |
| March 31, 2025 | $134.0K | -2.2% | +0.0% |
| December 31, 2024 | $134.0K | -2.9% | -0.7% |
| September 30, 2024 | $135.0K | -2.9% | -0.7% |
| June 30, 2024 | $136.0K | -2.9% | -0.7% |
| March 31, 2024 | $137.0K | -2.8% | -0.7% |
| December 31, 2023 | $138.0K | -2.1% | -0.7% |
- IGC Pharma, Inc. showed a decrease of -2.2% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: